InSights Videos

Innovation in the Race to Develop COVID-19 Vaccines

Innovation in the Race to Develop COVID-19 Vaccines

Vaccines are considered to be one of the greatest public health achievements of the last century, so when the COVID-19 pandemic brought the world to a stop, all energies were focused on bringing a vaccine to market. With multiple vaccines now approved and being...

Innovation in the Race to Develop COVID-19 Vaccines

How to achieve success in deal making

Hard lessons from 30 years of experience  A conversation with Fintan Walton, Founder of PharmaVentures Tony Jones, Chief Executive of One Nucleus, caught up with Fintan Walton to discuss the evolution of the deal making processes, where it is going in the...

Innovation in the Race to Develop COVID-19 Vaccines

How is M&A Shifting the Pharma Manufacturing Landscape?

Innovative manufacturing technologies are creating fresh deal-making opportunities for Pharma Manufacturers and CDMOs across both small and large molecule sectors, which are in turn transforming the pharma manufacturing landscape. Partnerships and mergers are a key...

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm. Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in...

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

The Divestment Challenge Interview

In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome. Paul Larsmon spoke with leading...

Contract Manufacturing in the Pharmaceutical Industry: Recipharm

Why you should make South Korea a deal making target

Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many...

Featured Videos

Manufacturing Operations Divestment Expertise

Visit our YouTube channel for more videos

Blog Articles

Our Termsheet

White Papers

Diagnostics

More important than ever, but there’s still a way to go. Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company it formed in 2016 and spun out. Illumina retained a 12% stake in the business and has...

Our News